TY  - CHAP
M1  - Book, Section
TI  - Menopause and Menstruation-Related Disorders
A1  - Cieri-Hutcherson, Nicole E.
A1  - Barnes, Kylie N.
A2  - Chisholm-Burns, Marie A.
A2  - Schwinghammer, Terry L.
A2  - Malone, Patrick M.
A2  - Kolesar, Jill M.
A2  - Bookstaver, P. Brandon
A2  - Lee, Kelly C.
PY  - 2022
T2  - Pharmacotherapy Principles & Practice, 6e
AB  - LEARNING  OBJECTIVESUpon  completion  of  the  chapter,  the  reader  will  be  able  to:Describe  the  underlying  etiology  of  dysmenorrhea,  amenorrhea,  anovulatory  bleeding,  heavy  menstrual  bleeding,  and  menopause.Explain  the  physiologic  changes  associated  with  dysmenorrhea,  amenorrhea,  anovulatory  bleeding,  heavy  menstrual  bleeding,  and  menopause.Identify  the  signs  and  symptoms  associated  with  dysmenorrhea,  amenorrhea,  anovulatory  bleeding,  heavy  menstrual  bleeding,  and  menopause.Determine  the  desired  therapeutic  outcomes  for  patients  with  dysmenorrhea,  amenorrhea,  anovulatory  bleeding,  heavy  menstrual  bleeding,  and  patients  taking  menopausal  hormone  therapy  (MHT).Explain  how  to  evaluate  a  patient  for  the  appropriate  use  of  MHT.Recommend  appropriate  nonpharmacologic  and  pharmacologic  interventions  for  dysmenorrhea,  amenorrhea,  anovulatory  bleeding,  heavy  menstrual  bleeding,  and  menopausal  symptoms.Design  a  monitoring  plan  to  assess  the  safety  and  effectiveness  of  pharmacotherapy  for  dysmenorrhea,  amenorrhea,  anovulatory  bleeding,  heavy  menstrual  bleeding,  and  a  patient  taking  MHT.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/10/04
UR  - ppp.mhmedical.com/content.aspx?aid=1187016668
ER  -